Paris, December 6, 2021 – Expleo, the global engineering, technology and consulting service provider, has signed a 28-million-euro agreement to acquire Assystem Care, the dedicated life sciences and chemical division of Assystem.
Assystem Care, which is expected to achieve revenues of 39 million euros in 2021, employs nearly 400 people in France, Belgium, and Switzerland. Expleo plans to grow the newly acquired business into its fifth largest business revenue-wise.
With 30 years-experience in health and life sciences, Assystem Care works with some of the world’s largest healthcare, biopharmaceutical, medical device, prognosis, agribusiness, fine chemicals, and cosmetics companies, to provide compliance, quality, and validation services. Its offer includes end-to-end engineering, quality, and performance management throughout the product lifecycle.
Assystem Care’s nearly 400-strong team is primarily located in France, with an additional presence in Belgium and Switzerland. The division is expected to generate around 39 million euros in revenue by the end of 2021. Expleo’s acquisition of Assystem Care will be effective on 1 January 2022.
Through this acquisition, Expleo becomes a critical player in a fast-growing industry.
For several years, Expleo has put its digital and engineering expertise to use in the areas of health and medicine. Its client portfolio features leading companies in the pharma, biotech, MedTech and in-vitro diagnostic sectors.
Assystem Care’s acquisition enables Expleo to bring together teams with complementary skills, who can operate across their clients’ industrial value chain.
Expleo is a leader in IT/digital activities including product lifecycle management, data science, virtual reality, automation / robotic process automation (RPA) and in activities related to manufacturing and supply chains. The integration of Assystem Care’s teams will bring additional expertise on compliance, quality and validation.
This acquisition will not affect on-going projects and will, in the long-term, make it possible to create synergies to support clients on new projects with larger scope, and an international footprint.
This acquisition, is in line with the strategic roadmap initiated in 2020 by its CEO Rajesh Krishnamurthy, and will enable Expleo to accelerate its development and branch out into growth markets.
Rajesh Krishnamurthy, Expleo’s CEO, said: “This acquisition is a great opportunity for Expleo. In a context of never-ending innovations in the life sciences and chemical sectors, combining Expleo’s capabilities in digital transformation with Assystem Care’s industry knowledge and regulatory expertise will create value for our clients, everywhere in the world. For our teams, this acquisition is a natural fit, as Expleo and Assystem share a common history, values and culture”.
Dominique Louis, Assystem’s CEO, added: “We are very happy for this process to take place with Expleo, a company that Assystem is a shareholder of*. We are confident that Expleo will provide teams with an ideal framework where they can keep on developing their unique expertise and broaden their offers. Expleo is the perfect acquirer, providing deep knowledge on how to accompany players in the industry throughout their production cycles”.
* Assystem holds 39% of Expleo’s shares
Senior Communications Manager
+44 (0)7711 385 637